Role of neurokinin-1 receptor antagonists in chemotherapy-induced emesis: Summary of clinical trials

Cancer Investigation

Volumn 22, Issue 4, 2004, Pages 569-576

  Navari, Rudolph M ^a  

^a UNIVERSITY OF NOTRE DAME   (United States)

Author keywords

5 HT3 receptor antagonists; Antiemetics; Chemotherapy induced emesis; NK 1 receptor antagonists

Indexed keywords

2 [1 [3,5 BIS(TRIFLUOROMETHYL)PHENYL]ETHOXY] 3 (4 FLUOROPHENYL) 4 (3 OXO 1 PHOSPHORYL 1,2,4 TRIAZOL 5 YLMETHYL)MORPHOLINE; 3 (2 METHOXY 5 TRIFLUOROMETHOXYBENZYLAMINO) 2 PHENYLPIPERIDINE; APREPITANT; BUTYROPHENONE DERIVATIVE; DEXAMETHASONE; DOLASETRON MESILATE; DOPAMINE RECEPTOR BLOCKING AGENT; DROPERIDOL; EZLOPITANT; GRANISETRON; HALOPERIDOL; METOCLOPRAMIDE; NEUROKININ 1 RECEPTOR ANTAGONIST; ONDANSETRON; PALONESETRON; PHENOTHIAZINE DERIVATIVE; RAMOSETRON; SEROTONIN 3 ANTAGONIST; SEROTONIN ANTAGONIST; SUBSTANCE P ANTAGONIST; TROPISETRON; UNCLASSIFIED DRUG;

AKATHISIA; ANOREXIA; BONE MARROW TRANSPLANTATION; CONSTIPATION; DIARRHEA; EXTRAPYRAMIDAL SYMPTOM; HEADACHE; HUMAN; NAUSEA; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; VOMITING;

ANTIEMETICS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; DRUG THERAPY, COMBINATION; HUMANS; MORPHOLINES; RECEPTORS, NEUROKININ-1; RECEPTORS, SEROTONIN, 5-HT3; VOMITING;

EID: 8644250381     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.1081/CNV-200027137     Document Type: Review

References (46)

1. Griffin, A.M.; Butow, P.N.; Coates, A.S.; Childs, A.M.; Ellis, P.M.; Dunn, S.M.; Tattersal, M.H. On the receiving end. V. Patient perceptions of the side effects of cancer chemotherapy in 1993. Ann. Oncol. 1996, 7, 189-195.
2. Osba, D.; Zee, B.; Warr, D.; Kaizer, L.; Latreille, J.; Pater, J. Quality of life studies in chemotherapy induced emesis. Oncology 1996, 53 (Suppl 1), 92-95.
3. Laszlo, J.; Lucas, V.S., Jr. Emesis as a critical problem in chemotherapy. N. Engl. J. Med. 1981, 305, 948-949.
4. Navari, R.M.; Kaplan, H.G.; Gralla, R.J.; Grunberg, S.M.; Palmer, R.; Fitts, D. Efficacy and safety of granisetron, a selective 5-hydroxytryptamine receptor antagonist, for the prevention of nausea and vomiting induced by high dose cisplatin. J. Clin. Oncol. 1994, 12, 2204-2210.
5. Navari, R.M.; Gandara, D.; Hesketh, P.; Hall, S.; Maillard, J.; Ritter, H.; Friedman, D.; Fitts, D. Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin induced emesis. J. Clin. Oncol. 1995, 13, 1242-1248.
6. Perez, E.A. Review of the preclinical pharmacology and comparative efficacy of 5-hydroxytryptamine-3 receptor antagonists for chemotherapy induced emesis. J. Clin. Oncol. 1995, 13, 1036-1043.
7. Morrow, G.R.; Hickok, J.T.; Rosenthal, S.N. Progress in reducing nausea and emesis. Comparisons of ondansetron, granisetron, and tropisetron. Cancer 1995, 76, 343-357.
8. Mantovani, G.; Maccio, A.; Bianch, A.; Curreli, L.; Ghiani, M.; Proto, E.; Santona, M.C. Comparison of granisetron versus ondansetron versus tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer; a randomized controlled trial. Cancer 1996, 77, 941-948.
9. Hesketh, P.; Navari, R.M.; Grote, T.; Gralla, R.; Hainsworth, J.; Kris, M.; Anthony, L.; Khovasteh, A.; Tapazoglou, E.; Benedict, C.; Hahne, W. Double blind randomized comparison of the antiemetic efficacy of intravenous dolasetron and intravenous ondansetron in the prevention of acute cisplatin induced emesis in patients with cancer. J. Clin. Oncol. 1996, 14, 2242-2249.
10. The Italian Group for Antiemetic Research. Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer. N. Engl. J. Med. 1995, 332, 1-5.
11. Hesketh, P.J.; Harvey, W.H.; Harker, W.G.; Beck, T.M.; Ryan, T.; Bricker, L.J.; Kishja, J.A.; Murphy, W.K.; Hainsworth, J.D.; Haley, B. A randomized double blind comparison of intravenous ondansetron alone and in combination with intravenous dexamethasone in the prevention of high dose cisplatin induced emesis. J. Clin. Oncol. 1994, 12, 596-600.
12. Perez, E.A.; Navari, R.M.; Kaplan, H.G.; Gralla, R.J.; Grunberg, S.M.; Palmer, R.H.; Fitts, D. Efficacy and safety of different doses of granisetron for the prophylaxis of cisplatin induced emesis. Suppl. Care Cancer 1997, 5, 31-37.
13. Kris, M.G.; Pendergrass, K.B.; Navari, R.M.; Grote, T.H.; Nelson, A.M.; Thomas, V.; Ferguson, B.B.; Alman, D.S.; Pizzo, B.A.; Baker, T.W.; Fernando, I.V.; Chernoff, S.B. Prevention of acute emesis following high dose cisplatin with the combination of oral dolasetron and dexamethasone. J. Clin. Oncol. 1997, 15, 2135-2138.
14. Italian Group for Antiemetic Research. Double blind dose finding study of four intravenous doses of dexamethasone in the prevention of cisplatin induced acute emesis. J. Clin. Oncol. 1998, 16, 2937-2942.
15. Beck, T.M.; York, M.; Chang, A.; Navari, R.M.; Harvey, W.H.; Meshad, M.; Griffin, D.; Wenta, A. Oral ondansetron 8 mg twice daily is as effective as 8 mg three times daily in the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy. Cancer Investig. 1997, 15, 297-303.
16. Kaizer, L.; Warr, D.; Hoskins, P.; Latreille, J.; Lofters, W.; Yau, J.; Palmer, M.; Zee, B.; Levy, M.; Pater, J. Effect of schedule and maintenance on the antiemetic efficacy of ondansetron combined with dexamethasone in acute and delayed nausea and emesis in patients receiving moderately emetogenic chemotherapy: a phase III trial by the National Cancer Institute of Canada clinical trials group. J. Clin. Oncol. 1994, 12, 1050-1057.
17. Navari, R.M.; Madajcwicz, S.; Anderson, N.; Tchekmedyian, N.S.; Whaley, W.; Garewal, H.; Beck, T.M.; Chang, A.Y.; Greenberg, B.; Caldwell, K.C. Oral ondansetron for the control of cisplatin-induced delayed emesis: a large, multicenter, double-blind, randomized comparative trial of ondansetron versus placebo. J. Clin. Oncol. 1995, 13, 2408-2416.
18. Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer: prevention of chemotherapy and radiotherapy-induced emesis: results of perugia consensus conference. Ann. Oncol. 1998, 9, 811-819.
19. Latreille, J.; Pater, J.; Johnston, D.; Laberge, F.; Stewart, D.; Rusthoven, J.; Hoskins, P.; Findlay, B.; McMurtrie, E.; Yelle, L.; Williams, C.; Walde, D.; Ernst, S.; Dhaliwal, H.; Warr, D.; Shepherd, F.; Mee, D.; Nishimura, L.; Osoba, D.; Zee, B. Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy. J. Clin. Oncol. 1998, 16, 1174-1178.
20. The Italian Group for Antiemetic Research. Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy. N. Engl. J. Med. 2000, 342, 1554-1559.
21. Kris, M.G.; Gralla, R.J.; Tyson, L.B. Controlling delayed vomiting: double blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin. J. Clin. Oncol. 1989, 7, 108-114.
22. Italian Group for Antiemetic Research. Ondansetron versus metoclopramide, both combined with dexamethasone, in the prevention of cisplatin induced delayed emesis. J. Clin. Oncol. 1997, 15, 124-130.
23. Gebbis, V.; Testa, A.; Valenza, R.; Cannata, G.; Tirrito, M.L.; Gabbia, N. Oral granisetron with or without methylprednisolone versus metoclopramide plus methylprednisolone in the management of delayed nausea and vomiting induced by cisplatin-based chemotherapy. Cancer 1995, 76, 1821-1828.
24. Pater, J.L.; Lofters, W.S.; Zee, B.; Dempsey, E.; Walde, D.; Moquin, J.P.; Wilson, K.; Hoskins, P.; Guevin, R.M.; Verma, S.; Navari, R.M.; Krook, J.E.; Hainsworth, J.; Palmer, M.; Chin, C. The role of the 5 HT3 antagonists' ondansetron and dolasetron in the control of delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Ann. Oncol. 1997, 8, 181-185.
25. Koo, W.O.; Ang, P.T. Role of maintenance oral dexamethasone in prophylaxis of delayed emesis caused by moderately emetogenic chemotherapy. Ann. Oncol. 1996, 7, 71-74.
26. Kaizer, L.; Warr, D.; Hoskins, P.; Latreille, J.; Lofters, W.; Yau, J.; Palmer, M.; Zie, B.; Levy, M.; Pater, J. Effect of schedule and maintenance on the antiemetic efficacy of ondansetron combined with dexamethasone in acute and delayed nausea and emesis in patients receiving moderately emetogenic chemotherapy: a phase III trial by the National Cancer Institute of Canada trials group. J. Clin. Oncol. 1994, 12, 1050-1057.
27. Borison, H.L.; McCarthy, L.E. Neuropharmacology of chemotherapy-induced emesis. Drugs 1983, 25 (Suppl 1), 8-17.
28. Longmore, J.; Swain, C.; Hill, R. Neurokinin receptors. Drug News Perspect. 1995, 8, 5-23.
29. Snider, R.M.; Constantine, J.W.; Lowe, J.A.; Longo, R.P.; Lebel, W.S.; Woody, H.A.; Drozda, S.E.; Desai, M.C.; Viniok, F.J.; Spencer, R.W. A potent nonpeptide antagonist of the substance P (NK-1) receptor. Science 1991, 251, 435-437.
30. Bountra, C.; Bruce, K.; Dale, T.; Garner, C.; Jordan, C.T.; Wissel, D.; Ward, P. Anti-emetic profile of a non-peptide neurokinin NK-1 receptor antagonist, CP-99,994, in ferrets. Eur. J. Pharmacol. 1993, 249, R3-R4.
31. Watson, J.W.; Gonsalves, S.F.; Rossa, A.A.; McLean, S.; Seeger, T.; Obsach, S.; Andrews, P.L. The anti-emetic effects of CP-99,994 in the ferret and the dog: role of the nk1 receptor. Br. J. Pharmacol. 1995, 115, 84-94.
32. Beattie, D.T.; Beresford, I.J.; Connor, H.E.; Marshall, F.H.; Hawcock, A.B.; Hagan, R.M.; Bowers, J.; Birch, P.J.; Ward, P. The pharmacology of GR203040, a novel, potent and selective non-peptide tachykinin NK-1 receptor antagonist. Br. J. Pharmacol. 1995, 116, 3149-3157.
33. Tattersall, F.D.; Rycroft, W.; Cumberbatch, M.; Mason, G.; Tye, S.; Williamson, D.J.; Hale, J.J.; Mills, S.G.; Finke, P.E.; MacCoss, M.; Sadowski, S.; Ber, E.; Cascieri, M.; Hill, R.G.; MacIntyre, E.; Hargreaves, R.J. The novel NK-1 receptor antagonist MK-0869 (L-754,030) and its water soluble phosphoryl prodrug L-758,298 inhibit acute and delayed cisplatin-induced emesis in ferrets. Neuropharmacology 2000, 39 (4), 652-663.
34. Gonsalves, S.; Watson, J.; Ashron, C. Broad spectrum antiemetic effects of CP-122,721, a tachykinin NK-1 receptor antagonist in ferrets. Eur. J. Pharmacol. 1996, 305, 181-185.
35. Kris, M.G.; Radford, J.E.; Pizzo, B.A.; Inabinet, R.; Hesketh, A.; Hesketh, P.J. Use of a NK-1 receptor antagonist to prevent delayed emesis after cisplatin (letter). J. Natl. Cancer Inst. 1997, 89, 817-818.
36. Cocquyt, V.; Van Belle, S.; Reinhardt, R.R.; Decramer, M.L.; O'Brien, H.; Schellens, J.H.; Borms, M.; Verseke, L.; VanAelst, F.; DeSmet, M.; Carides, A.D.; Eldridge, K.; Gertz, B.J. Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis. Eur. J. Cancer 2001, 37, 835-842.
37. Navari, R.M.; Reinhardt, R.R.; Gralla, R.J.; Kris, M.G.; Hesketh, P.J.; Khovasteth, A.; Kindler, H.; Grote, T.H.; Pendergrass, K.; Grunberg, S.M.; Carides, A.D.; Gertz, B.J. Reduction of cisplatin-induced emesis by a selective neurokin-1 receptor antagonist. N. Engl. J. Med. 1999, 340, 190-195.
38. Hesketh, P.J.; Gralla, R.J.; Webb, R.T.; Ueno, W.; Delprete, S.; Bachinsky, M.E.; Dirlani, N.L.; Stack, C.B.; Silberman, S.L. Randomized phase II study of the neurokinin-1 receptor antagonist CJ-11,974 in the control of cisplatin-induced emesis. J. Clin. Oncol. 1999, 17, 338-343.
39. Van Belle, S.; Liechinitser, M.; Navari, R.M.; Garin, A.M.; Decramer, M.L.; Riviera, A.; Thant, M.; Brestan, E.; Bui, B.; Eldridge, K.; DeSmet, M.; Michaels, N.; Reinhardt, R.R.; Carides, A.D.; Evans, J.K.; Gertz, B.J. Prevention of cisplatin-induced emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869. Cancer 2002, 94, 3032-3041.
40. Campos, D.; Pereira, J.R.; Reinhardt, R.R.; Cardacedo, C.; Poli, S.; Vogel, C.; Martinel-Cedillo, J.; Erazo, A.; Wittreich, J.; Erikson, L.O.; Carides, A.D.; Gertz, B.J. Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone. J. Clin. Oncol. 2001, 19, 1759-1767.
41. Chawla, S.P.; Grunberg, S.M.; Gralla, R.J.; et al. Establishing the dose of the oral NK-1 antagonist aprepitant for chemotherapy induced nausea and vomiting. Cancer 2003, 97, 2290-2300.
42. Hesketh, P.J.; Grunberg, S.M.; Gralla, R.J.; et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind placebo-controlled trial in patients receiving high-dose cisplatin-the aprepitant protocol 052 study group. J. Clin. Oncol. 2003, 21, 4112-4119.
43. Poli-Bigelli, S.; Rodrigues-Pereira, J.; Carides, A.D.; et al. Addition of the neurokinin-1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Cancer 2003, 97, 3090-3098.
44. deWitt, R.; Herrstedt, J.; Rapoport, B.L.; et al. Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy. J. Clin. Oncol. 2003, 21, 4105-4111.
45. deWitt, R.; Herrstedt, J.; Rapoport, B.; et al. The oral NK-1 antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomized, placebo-controlled phase III clinical trials. European. J. Cancer. 2004, 40, 403-410.
46. Warr, D.G.; Eisenberg, P.; Hesketh, P.J.; et al. Phase III double-blind study to assess an aprepitant-containing regimen for the prevention of nausea and vomiting due to moderately emetogenic chemotherapy. Proc. Am. Soc. Clin. Oncol. 2004, Abstract 8007.